Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer
Q Wang, H Wang, P Li, H Zhu, C He, Z Ma… - The American journal of …, 2010 - Elsevier
Abstract Treatment of unresectable nonsmall cell lung cancer (NSCLC) remains
challenging. The epidermal growth factor receptor tyrosine kinase inhibitors are promising …
challenging. The epidermal growth factor receptor tyrosine kinase inhibitors are promising …
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
T Kato, I Casarini, M Cobo, C Faivre-Finn… - Lung Cancer, 2023 - Elsevier
Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
Perioperative targeted therapy for oncogene-driven NSCLC
SY Liu, JT Zhang, KH Zeng, YL Wu - Lung Cancer, 2022 - Elsevier
Targeted therapy has stepped into the perioperative treatment arena and launched a radical
revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer …
revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Gefitinib Versus Adjuvant Chemotherapy in Patients with Stage II-IIIA Non–Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center …
H Xie, H Wang, L Xu, M Li, Y Peng, X Cai, Z Feng… - Clinical Lung Cancer, 2018 - Elsevier
Background The superior efficacy of first-line treatment with gefitinib over that of standard
chemotherapy was demonstrated in patients with advanced non–small-cell lung cancer …
chemotherapy was demonstrated in patients with advanced non–small-cell lung cancer …
[PDF][PDF] Adjuvant osimertinib in EGFR-mutated non-small-cell lung cancer
D Planchard - N Engl J Med, 2020 - bookcafe.yuntsg.com
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have completely
reinvented therapeutic care for patients with metastatic non–small-cell lung cancer (NSCLC) …
reinvented therapeutic care for patients with metastatic non–small-cell lung cancer (NSCLC) …
[HTML][HTML] Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label …
C Lv, W Fang, N Wu, W Jiao, S Xu, H Ma, J Wang… - Lung Cancer, 2023 - Elsevier
Objectives Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI), has been approved for EGFR-mutant non-small-cell lung cancer …
kinase inhibitor (TKI), has been approved for EGFR-mutant non-small-cell lung cancer …
Role of anti-EGFR targeted therapies in stage III locally advanced non-small cell lung cancer: give or not to give?
Abstract Purpose of Review Identification of targetable mutations such as EGFR has allowed
opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs …
opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs …